Semaglutide
A GLP-1 receptor agonist peptide studied for incretin signaling, appetite regulation, and metabolic research models.
What Semaglutide is
Semaglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1). In peer-reviewed literature it is extensively characterized as a GLP-1 receptor agonist that augments glucose-dependent insulin signaling, slows gastric emptying, and influences central appetite pathways. Prescription drug products containing semaglutide are FDA-approved under separate brand identities for specific indications; those approved finished drug products are not the same as research-grade bulk peptide.
Researchers use research-grade semaglutide to study incretin biology, energy-balance circuits, cardiometabolic biomarkers, and comparative pharmacology versus other GLP-1 or dual/triple agonists. The research record includes large clinical programs on approved formulations, but laboratory RUO material is a distinct supply channel.
Critical compliance note: research-grade semaglutide offered for laboratory use is Research Use Only. It is not Ozempic, Wegovy, Rybelsus, or any other FDA-approved drug product. It is not for human consumption, compounding substitution, or clinical treatment. Figures below summarize published research and approved-product literature for education only.
Semaglutide has been studied in human trials, which is not true of most compounds in this library. The figures below come from that work.
How it works
Semaglutide binds the GLP-1 receptor, a Gs-coupled GPCR, raising cAMP in pancreatic beta cells and other target tissues. Downstream signaling supports glucose-dependent insulin release, suppresses glucagon under appropriate conditions, delays gastric emptying, and modulates hypothalamic and brainstem circuits involved in satiety. Structural modifications (including fatty-acid acylation) prolong albumin binding and extend half-life relative to native GLP-1, which is rapidly degraded by DPP-4.
Where this compound shows up in research
Metabolic disease, endocrinology, and obesity-biology groups are the primary research audience. Pharmaceutical and academic labs also use semaglutide as a reference GLP-1 agonist when benchmarking newer dual or triple agonists in preclinical and translational models.
What the research examines
These describe where the compound shows up in published work. None of them should be read as an established outcome.
How it appears in the literature
What the published work actually used. Reference only, not instructions.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Published clinical titration ranges for approved once-weekly injectable semaglutide products (reference only) | 250 mcg – 2.4 mg | once weekly | subcutaneous |
| Early-phase / lower exposure bands commonly discussed in protocol literature | 250 mcg – 500 mcg | once weekly | subcutaneous |
Handling & storage
Store lyophilized peptide cold, dry, and protected from light. After reconstitution, refrigerate and minimize freeze-thaw cycles. Follow the laboratory SOP for beyond-use dating of reconstituted aliquots.
Notes on combined research
In experimental designs, semaglutide is often compared rather than combined with other incretin agents such as tirzepatide, retatrutide, or survodutide to map mono- versus multi-receptor pharmacology. Metabolic studies may also track concurrent lifestyle, dietary, or exercise variables because GLP-1 pathway readouts are highly context dependent.
Semaglutide questions
Published once-weekly injectable schedules for approved products generally span about 0.25 mg to 2.4 mg. Those figures describe regulated drug products, not research-grade RUO peptide, and are not use instructions.
No. Approved brand products are finished pharmaceutical drugs manufactured and labeled under FDA authority. Research-grade semaglutide is a laboratory chemical for Research Use Only and is not for human consumption.
It activates the GLP-1 receptor, increasing cAMP-dependent signaling that affects insulin and glucagon dynamics, gastric emptying, and central appetite pathways.
Fatty-acid modification and albumin binding substantially extend its half-life versus native GLP-1, supporting once-weekly exposure designs in many studies of long-acting formulations.
No. RUO research material is not a medicine, not a substitute for prescription therapy, and not intended for human use.
Research suppliers frequently list lyophilized vials in the 2 mg, 5 mg, or 10 mg class for assay preparation. Concentration after reconstitution depends on solvent volume chosen by the lab.
Gastrointestinal effects such as nausea are among the most frequently reported classes in approved-product trials. That clinical safety record belongs to regulated drug products, not RUO chemicals.
Read the research yourself
Verified against PubMed, one by one. A reference you cannot open is not evidence.
- The physiology of glucagon-like peptide 1.PubMed
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.PubMed
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.PubMed
- Semaglutide for the treatment of obesity.PubMed
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.PubMed